Copyright © 2002 by the European Society of Cardiology.
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)
a Hospital No. 64, Russian University of People's Friendship, Moscow, Russia
b Orion Pharma, Research Center, Espoo, Finland
c P. Stradin's Research and Teaching Hospital, Latvian Medical Academy, Riga, Latvia
d A.L. Myasnikov Institute of Cardiology, Cardiology Research Center, Moscow, Russia
e Cardiology Clinic, Sklifosovsky Research Institute for Emergency Medicine, Moscow, Russia
f Department of Gerontology and Geriatrics, Russian Medical Academy for Postgraduate Training, Moscow, Russia
g Department of Clinical Pharmacology, University of Helsinki, Finland
h Helsinki University Central Hospital, Cardiology Division, Helsinki, Finland
i Academic Medical Center, University of Amsterdam, The Netherlands
Received December 4, 2001; accepted December 12, 2001
Abstract
Aims To evaluate the safety and efficacy of levosimendan in patients with left ventricular failure complicating acute myocardial infarction.
Methods and Results Levosimendan at different doses (0·1–0·4µg.kg–1.min–1) or placebo were administered intravenously for 6h to 504 patients in a randomised, placebo-controlled, double-blind study. The primary end-point was hypotension or myocardial ischaemia of clinical significance adjudicated by an independent Safety Committee. Secondary end-points included risk of death and worsening heart failure, symptoms of heart failure and all-cause mortality. The incidence of ischaemia and/or hypotension was similar in all treatment groups (P=0·319). A higher frequency of ischaemia and/or hypotension was only seen in the highest levosimendan dose group. Levosimendan-treated patients experienced lower risk of death and worsening heart failure than patients receiving placebo, during both the 6h infusion (2·0% vs 5·9%; P=0·033) and over 24h (4·0% vs 8·8%; P=0·044). Mortality was lower with levosimendan compared with placebo at 14 days (11·7% vs 19·6%; hazard ratio 0·56 [95% CI 0·33–0·95];P =0·031) and the reduction was maintained at the 180-day retrospective follow-up (22·6% vs 31·4%; 0·67 [0·45-1·00],P =0·053).
Conclusions Levosimendan at doses 0·1–0·2µg.kg–1.min–1 did not induce hypotension or ischaemia and reduced the risk of worsening heart failure and death in patients with left ventricular failure complicating acute myocardial infarction. Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.
Key Words: Left ventricular failure, myocardial infarction, levosimendan, hypotension, ischaemia, mortality
f2 Correspondence: Professor Markku S. Nieminen, MD, PhD, FACC, Helsinki University Central Hospital, Department of Internal Medicine, Cardiology Division, 00029, Haartmaninkatu 4, Helsinki, Finland.
f1 All investigators and study sites are listed in the Appendix.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. B. Overgaard and V. Dzavik Inotropes and Vasopressors: Review of Physiology and Clinical Use in Cardiovascular Disease Circulation, September 2, 2008; 118(10): 1047 - 1056. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Segreti, K. C. Marsh, J. S. Polakowski, and R. M. Fryer Evoked Changes in Cardiovascular Function in Rats by Infusion of Levosimendan, OR-1896 [(R)-N-(4-(4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-Aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], Dobutamine, and Milrinone: Comparative Effects on Peripheral Resistance, Cardiac Output, dP/dt, Pulse Rate, and Blood Pressure J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 331 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Masutani, H.-J. Cheng, M. Hyttila-Hopponen, J. Levijoki, A. Heikkila, A. Vuorela, W. C. Little, and C.-P. Cheng Orally Available Levosimendan Dose-Related Positive Inotropic and Lusitropic Effect in Conscious Chronically Instrumented Normal and Heart Failure Dogs J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 236 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. N. Banfor, L. C. Preusser, T. J. Campbell, K. C. Marsh, J. S. Polakowski, G. A. Reinhart, B. F. Cox, and R. M. Fryer Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H238 - H248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. V. McMurray, J. R. Teerlink, G. Cotter, R. C. Bourge, J. G. F. Cleland, G. Jondeau, H. Krum, M. Metra, C. M. O'Connor, J. D. Parker, et al. Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure: The VERITAS Randomized Controlled Trials JAMA, November 7, 2007; 298(17): 2009 - 2019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kankaanranta, X. Zhang, R. Tumelius, M. Ruotsalainen, H. Haikala, E. Nissinen, and E. Moilanen Antieosinophilic Activity of Simendans J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 31 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. N. Stehr, T. Christ, B. Rasche, S. Rasche, E. Wettwer, A. Deussen, U. Ravens, T. Koch, and M. Hubler The Effects of Levosimendan on Myocardial Function in Ropivacaine Toxicity in Isolated Guinea Pig Heart Preparations Anesth. Analg., September 1, 2007; 105(3): 641 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mebazaa, M. S. Nieminen, M. Packer, A. Cohen-Solal, F. X. Kleber, S. J. Pocock, R. Thakkar, R. J. Padley, P. Poder, M. Kivikko, et al. Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure: The SURVIVE Randomized Trial JAMA, May 2, 2007; 297(17): 1883 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Pagel Levosimendan in Cardiac Surgery: A Unique Drug for the Treatment of Perioperative Left Ventricular Dysfunction or Just Another Inodilator Searching for a Clinical Application? Anesth. Analg., April 1, 2007; 104(4): 759 - 761. [Full Text] [PDF]
|
|
|
|
|
|
S. G. De Hert, S. Lorsomradee, S. Cromheecke, and P. J. Van der Linden The Effects of Levosimendan in Cardiac Surgery Patients with Poor Left Ventricular Function Anesth. Analg., April 1, 2007; 104(4): 766 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J T Parissis, S Adamopoulos, D Farmakis, G Filippatos, I Paraskevaidis, F Panou, E Iliodromitis, and D Th Kremastinos Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure Heart, December 1, 2006; 92(12): 1768 - 1772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Groban and J. Butterworth Perioperative management of chronic heart failure. Anesth. Analg., September 1, 2006; 103(3): 557 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. De Luca, W. S. Colucci, M. S. Nieminen, B. M. Massie, and M. Gheorghiade Evidence-based use of levosimendan in different clinical settings Eur. Heart J., August 2, 2006; 27(16): 1908 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gy. Papp, P. Pollesello, A. F. Varro, and A. S. Vegh Effect of Levosimendan and Milrinone on Regional Myocardial Ischemia/Reperfusion-Induced Arrhythmias in Dogs Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2006; 11(2): 129 - 135. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Tritapepe, V. De Santis, D. Vitale, M. Santulli, A. Morelli, I. Nofroni, P. E. Puddu, M. Singer, and P. Pietropaoli Preconditioning effects of levosimendan in coronary artery bypass grafting--a pilot study Br. J. Anaesth., June 1, 2006; 96(6): 694 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Egan, A. J. B. Clarke, S. Williams, A. D. Cole, J. Ayer, S. Jacobe, R. B. Chard, and D. S. Winlaw Levosimendan for Low Cardiac Output: A Pediatric Experience. J Intensive Care Med, May 1, 2006; 21(3): 183 - 187. [Abstract] [PDF]
|
|
|
|
 |
|
 S. G. Raja and B. S. Rayen Levosimendan in Cardiac Surgery: Current Best Available Evidence Ann. Thorac. Surg., April 1, 2006; 81(4): 1536 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Kass and R. J. Solaro Mechanisms and Use of Calcium-Sensitizing Agents in the Failing Heart Circulation, January 17, 2006; 113(2): 305 - 315. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Alhashemi Treatment of cardiogenic shock with levosimendan in combination with {beta}-adrenergic antagonists Br. J. Anaesth., November 1, 2005; 95(5): 648 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L Earl and J. T Fitzpatrick Levosimendan: A Novel Inotropic Agent for Treatment of Acute, Decompensated Heart Failure Ann. Pharmacother., November 1, 2005; 39(11): 1888 - 1896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Arteaga, C. M. Warren, S. Milutinovic, A. F. Martin, and R. J. Solaro Specific enhancement of sarcomeric response to Ca2+ protects murine myocardium against ischemia-reperfusion dysfunction Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2183 - H2192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. R. Dopfmer, J. P. Braun, J. Grosse, and W. Konertz Temporary left ventricular assist and levosimendan for coronary artery spasm Interactive CardioVascular and Thoracic Surgery, August 1, 2005; 4(4): 316 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Garcia-Gonzalez, A. Dominguez-Rodriguez, and J. J. Ferrer-Hita Utility of Levosimendan, a New Calcium Sensitizing Agent, in the Treatment of Cardiogenic Shock Due to Myocardial Stunning in Patients With ST-Elevation Myocardial Infarction: A Series of Cases J. Clin. Pharmacol., June 1, 2005; 45(6): 704 - 708. [Full Text] [PDF]
|
|
|
|
 |
|
 K. P. Bouki, G. Pavlakis, and E. Papasteriadis Management of Cardiogenic Shock Due to Acute Coronary Syndromes Angiology, March 1, 2005; 56(2): 123 - 130. [Abstract] [PDF]
|
|
|
|
|
|
H. Tachibana, H.-J. Cheng, T. Ukai, A. Igawa, Z.-S. Zhang, W. C. Little, and C.-P. Cheng Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H914 - H922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Braun, M. Schneider, M. Kastrup, and J. Liu Treatment of acute heart failure in an infant after cardiac surgery using levosimendan Eur. J. Cardiothorac. Surg., July 1, 2004; 26(1): 228 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Benlolo, C. Lefoll, V. Katchatouryan, D. Payen, and A. Mebazaa Successful Use of Levosimendan in a Patient with Peripartum Cardiomyopathy Anesth. Analg., March 1, 2004; 98(3): 822 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. McBride and C. M. White Levosimendan: Implications for Clinicians J. Clin. Pharmacol., October 1, 2003; 43(10): 1071 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Scoote, P A Poole-Wilson, and A J Williams The therapeutic potential of new insights into myocardial excitation-contraction coupling Heart, April 1, 2003; 89(4): 371 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kivikko, L. Lehtonen, W. S. Colucci, and on Behalf of the Study Investigators Sustained Hemodynamic Effects of Intravenous Levosimendan Circulation, January 7, 2003; 107(1): 81 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.J.S. Coats Positive inotropy for acute heart failure complicating myocardial infarction Eur. Heart J., September 2, 2002; 23(18): 1405 - 1406. [Full Text] [PDF]
|
|